UK Biotech MiroBio Agrees to USD 405m Gilead Sciences Buyout.

MANews-(C)2009-2022

UK-based biotechnology company MiroBio Ltd has entered into a definitive agreement with US-based Gilead Sciences (NASDAQ: GILD), Inc. to be acquired for approximately USD 405m in cash, subject to customary adjustments, the firm said.

MiroBio is focused on restoring immune balance with agonists targeting immune inhibitory receptors.

MiroBio was spun out of the University of Oxford in 2019 to develop a new class of medicines, called immune checkpoint agonists, to treat autoimmune diseases by restoring balance to the immune system.

Oxford Science Enterprises and Samsara BioCapital co-led a GBP 27m series A investment in 2019 and Medicxi invested in the company in June 2022 when it led an GBP 80 m series B financing.

Nick Williams, who was recently appointed as Partner at Medicxi, oversaw the investment and joined MiroBio's board.

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum.

Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need.

MiroBio is a...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT